Factors associated with disease progression and viral replication in patients with chronic hepatitis B virus infection

  • Authors:
    • Jing Jia
    • Yonghong Li
    • Chaojun Wei
    • Rui Guo
    • Hui Xu
    • Yanjuan Jia
    • Yu Wu
    • Yuanting Li
    • Zhenhong Wei
    • Xiaoming Qi
    • Zhenhao Li
    • Xiaoling Gao
  • View Affiliations

  • Published online on: April 11, 2019     https://doi.org/10.3892/etm.2019.7482
  • Pages: 4730-4740
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Hepatitis B virus (HBV) infection remains a severe clinical concern in China. Of note, the progression of HBV infection varies between different populations. To identify the factors that influence the disease progression and prognosis, a total of 478 chronic HBV‑infected patients were enrolled, and liver function parameters, HBV DNA levels and hepatic fibrosis indices were analyzed. First, the results demonstrated a significant difference in hepatitis B e antigen (HBeAg) expression between male and female patients (χ2=4.061, P=0.044). Furthermore, when comparing either HBeAg‑negative or ‑positive male and female patients, males exhibited a greater variation in HBV DNA levels. Although significant differences between male and female patients in certain abnormal ratios of liver function parameters were identified, a trend in the differences was observed in the HBeAg‑negative and ‑positive groups. When considering age, the results of the present study confirmed that HBV DNA levels decreased with advanced age, and the values of the majority of biomarkers exhibited an evident decreasing trend with increasing age. In addition, it was demonstrated that all HBeAg seropositive patients had higher levels of hepatic fibrosis indexes and higher abnormal ratios of hepatic fibrosis values in their serum when compared with those of HBeAg seronegative patients, particularly with regard to serum IV collagen. The present results revealed that HBV DNA replication was closely associated with liver function; however, it was notable that in HBeAg‑negative patients, the association between HBV DNA levels and liver function was particularly significant among subjects aged <61. Furthermore, this result was not observed in HBeAg‑positive patients. In conclusion, the present study indicated the importance of host factors (including sex and age) and viral factors (including HBeAg expression pattern and HBV DNA levels) in the progression of chronic HBV infection, and its influence regarding prognosis and treatment. The present results provide a foundation for clinical management strategies for chronic HBV infection, particularly in individual schemes.

References

1 

Liu J, Zhang S, Wang Q, Shen H, Zhang M, Zhang Y, Yan D and Liu M: Seroepidemiology of hepatitis B virus infection in 2 million men aged 21–49 years in rural China: A population-based, cross-sectional study. Lancet Infect Dis. 16:80–86. 2016. View Article : Google Scholar : PubMed/NCBI

2 

Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, et al: Reprint of: Epidemiological serosurvey of Hepatitis B in China-declining HBV prevalence due to Hepatitis B vaccination. Vaccine. 31 (Suppl 9):J21–J28. 2013. View Article : Google Scholar : PubMed/NCBI

3 

Wang Y, Zhou H, Zhang L, Zhong Q, Wang Q, Shen H, Zhang M, Huang Y, Wang A, Nelson K, et al: Prevalence of chronic hepatitis B and status of HBV care among rural women who planned to conceive in China. Sci Rep. 7:120902017. View Article : Google Scholar : PubMed/NCBI

4 

Trépo C, Chan HL and Lok A: Hepatitis B virus infection. Lancet. 384:2053–2063. 2014. View Article : Google Scholar : PubMed/NCBI

5 

Lu F, Li T, Liu S and Zhuang H: Epidemiology and prevention of hepatitis B virus infection in China. J Viral Hepat. 17 (Suppl 1):S4–S9. 2010. View Article : Google Scholar

6 

Biswas A, Panigrahi R, Pal M, Chakraborty S, Bhattacharya P, Chakrabarti S and Chakravarty R: Shift in the hepatitis B virus genotype distribution in the last decade among the HBV carriers from eastern India: Possible effects on the disease status and HBV epidemiology. J Med Virol. 85:1340–1347. 2013. View Article : Google Scholar : PubMed/NCBI

7 

Moura IF, Lopes EP, Alvarado-Mora MV, Pinho JR and Carrilho FJ: Phylogenetic analysis and subgenotypic distribution of the hepatitis B virus in Recife, Brazil. Infect Genet Evol. 14:195–199. 2013. View Article : Google Scholar : PubMed/NCBI

8 

Wang SH, Chen PJ and Yeh SH: Gender disparity in chronic hepatitis B: Mechanisms of sex hormones. J Gastroenterol Hepatol. 30:1237–1245. 2015. View Article : Google Scholar : PubMed/NCBI

9 

Zheng B, Zhu Y, Wang H and Chen L: Gender disparity in hepatocellular carcinoma (HCC): Multiple underlying mechanisms. Sci China Life Sci. 60:575–584. 2017. View Article : Google Scholar : PubMed/NCBI

10 

Tan Y, Ye Y, Zhou X, Chen L and Wen D: Age as a predictor of significant fibrosis features in HBeAg-negative chronic hepatitis B virus infection with persistently normal alanine aminotransferase. PLoS One. 10:e01234522015. View Article : Google Scholar : PubMed/NCBI

11 

Zhang H, Huo M, Chao J and Liu P: Application of bayesian approach to cost-effectiveness analysis of antiviral treatments in chronic Hepatitis B. PLoS One. 11:e01619362016. View Article : Google Scholar : PubMed/NCBI

12 

Everson GT, Shiffman ML, Hoefs JC, Morgan TR, Sterling RK, Wagner DA, Lauriski S, Curto TM, Stoddard A and Wright EC; HALT-C Trial Group, : Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: Results from the Hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology. 55:1019–1029. 2012. View Article : Google Scholar : PubMed/NCBI

13 

Ghany MG, Lok AS, Everhart JE, Everson GT, Lee WM, Curto TM, Wright EC, Stoddard AM, Sterling RK, Di Bisceglie AM, et al: Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology. 138:136–146. 2010. View Article : Google Scholar : PubMed/NCBI

14 

Qi Y, Gao Z, Xu G, Peng B, Liu C, Yan H, Yao Q, Sun G, Liu Y, Tang D, et al: DNA polymerase kappa is a key cellular factor for the formation of covalently closed circular DNA of Hepatitis B virus. PLoS Pathog. 12:e10058932016. View Article : Google Scholar : PubMed/NCBI

15 

Zhang Z, Li A and Xiao X: Risk factors for intrauterine infection with hepatitis B virus. Int J Gynaecol Obstet. 125:158–161. 2014. View Article : Google Scholar : PubMed/NCBI

16 

Chan H, Tse C, Mo F, Koh J, Wong VW, Wong GL, Lam Chan S, Yeo W, Sung JJ and Mok TS: High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol. 26:177–182. 2008. View Article : Google Scholar : PubMed/NCBI

17 

Mommeja-Marin H, Mondou E, Blum M and Rousseau F: Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: Analysis and review of the literature. Hepatology. 37:1309–1319. 2003. View Article : Google Scholar : PubMed/NCBI

18 

Sanai FM, Helmy A, Bzeizi KI, Babatin MA, Al-Qahtani A, Al-Ashgar HA, Al-Mdani AS, Al-Akwaa A, Almutharea S, Khan MQ, et al: Discriminant value of serum HBV DNA levels as predictors of liver fibrosis in chronic hepatitis B. J Viral Hepat. 18:e217–e225. 2011. View Article : Google Scholar : PubMed/NCBI

19 

Yuen MF, Tanaka Y, Fong DY, Fung J, Wong DK, Yuen JC, But DY, Chan AO, Wong BC, Mizokami M and Lai CL: Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol. 50:80–88. 2009. View Article : Google Scholar : PubMed/NCBI

20 

Ozaki K, Matsui O, Gabata T, Kobayashi S, Koda W and Minami T: Confluent hepatic fibrosis in liver cirrhosis: Possible relation with middle hepatic venous drainage. Jpn J Radiol. 31:530–537. 2013. View Article : Google Scholar : PubMed/NCBI

21 

Shirvani-Dastgerdi E, Winer BY, Celià-Terrassa T, Kang Y, Tabernero D, Yagmur E, Rodríguez-Frías F, Gregori J, Luedde T, Trautwein C, et al: Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy. J Hepatol. 67:246–254. 2017. View Article : Google Scholar : PubMed/NCBI

22 

Xiang Y, Chen P, Xia JR and Zhang LP: A large-scale analysis study on the clinical and viral characteristics of hepatitis B infection with concurrence of hepatitis B surface or E antigens and their corresponding antibodies. Genet Mol Res. 16:2017. View Article : Google Scholar : PubMed/NCBI

23 

Chen P, Xie Q, Lu X, Yu C, Xu K, Ruan B, Cao H, Gao H and Li L: Serum HBeAg and HBV DNA levels are not always proportional and only high levels of HBeAg most likely correlate with high levels of HBV DNA: A community-based study. Medicine (Baltimore). 96:e77662017. View Article : Google Scholar : PubMed/NCBI

24 

Chinese Society of Hepatology of Chinese Medical Association, . The Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2015). Chinese Journal of experimental and Clinical Infectious Diseases (Electronic Edition). 19:1–18. 2015.

25 

Wang SH, Chen PJ and Yeh SH: Gender disparity in chronic hepatitis B: Mechanisms of sex hormones. J Gastroenterol Hepatol. 30:1237–1245. 2015. View Article : Google Scholar : PubMed/NCBI

26 

Wu DL, Xu GH, Lu SM, Ma BL, Miao NZ, Liu XB, Feng JH, Liu N, Zeng QL, Hou WK, et al: Age versus clinical virological characteristics in chronic hepatitis B virus infection: A case series study in China. Eur J Gastroenterol Hepatol. 24:406–413. 2012.PubMed/NCBI

27 

Dong J, Ying J, Qiu X, Lu Y and Zhang M: Advanced strategies for eliminating the cccDNA of HBV. Dig Dis Sci. 63:7–15. 2018. View Article : Google Scholar : PubMed/NCBI

28 

Samal J, Kandpal M and Vivekanandan P: HBeAg-induced miR-106b promotes cell growth by targeting the retinoblastoma gene. Sci Rep. 7:143712017. View Article : Google Scholar : PubMed/NCBI

29 

Yu Y, Wan P, Cao Y, Zhang W, Chen J, Tan L, Wang Y, Sun Z, Zhang Q, Wan Y, et al: Hepatitis B virus e antigen activates the suppressor of cytokine signaling 2 to repress interferon action. Sci Rep. 7:17292017. View Article : Google Scholar : PubMed/NCBI

30 

Wan DW, Tzimas D, Smith JA, Kim S, Araujo J, David R, Lobach I and Sarpel U: Risk factors for early-onset and late-onset hepatocellular carcinoma in Asian immigrants with hepatitis B in the United States. Am J Gastroenterol. 106:1994–2000. 2011. View Article : Google Scholar : PubMed/NCBI

31 

Lee SA, Kim H, Won YS, Seok SH, Na Y, Shin HB, Inn KS and Kim BJ: Male-specific hepatitis B virus large surface protein variant W4P potentiates tumorigenicity and induces gender disparity. Mol Cancer. 14:232015. View Article : Google Scholar : PubMed/NCBI

32 

Wong VW and Janssen HL: Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection? J Hepatol. 63:722–732. 2015. View Article : Google Scholar : PubMed/NCBI

33 

Furrer K, Rickenbacher A, Tian Y, Jochum W, Bittermann AG, Käch A, Humar B, Graf R, Moritz W and Clavien PA: Serotonin reverts age-related capillarization and failure of regeneration in the liver through a VEGF-dependent pathway. Proc Natl Acad Sci USA. 108:2945–2950. 2011. View Article : Google Scholar : PubMed/NCBI

34 

Zhang C and Cuervo AM: Restoration of chaperone-mediated autophagy in aging liver improves cellular maintenance and hepatic function. Nat Med. 14:959–965. 2008. View Article : Google Scholar : PubMed/NCBI

35 

LE Couteur D, Cogger V, McCuskey R, DE Cabo R, Smedsrød B, Sorensen KK, Warren A and Fraser R: Age-related changes in the liver sinusoidal endothelium: A mechanism for dyslipidemia. Ann NY Acad Sci. 1114:79–87. 2007. View Article : Google Scholar : PubMed/NCBI

36 

Dusséaux M, Masse-Ranson G, Darche S, Ahodantin J, Li Y, Fiquet O, Beaumont E, Moreau P, Rivière L, Neuveut C, et al: Viral load affects the immune response to HBV in mice with humanized immune system and liver. Gastroenterology. 153:1647–1661.e9. 2017. View Article : Google Scholar : PubMed/NCBI

37 

Choi JW, Kim SH, Seo JH, Cho YS, Won SY, Park BK, Jeon HH, Lee YK and Lee CK: Real world experience of telbivudine versus entecavir in patients with chronic Hepatitis B, including long-term outcomes after treatment modification. Yonsei Med J. 59:383–388. 2018. View Article : Google Scholar : PubMed/NCBI

38 

Wang ML, Chen EQ, Tao CM, Zhou TY, Liao J, Zhang DM, Wang J and Tang H: Pronounced decline of serum HBsAg in chronic hepatitis B patients with long-term effective nucleos(t)ide analogs therapy. Scand J Gastroenterol. 52:1420–1426. 2017. View Article : Google Scholar : PubMed/NCBI

39 

Kang SH, Yim HJ, Kim HR, Kang K, Suh SJ, Lee HJ, Yoon EL, Kim JH, Seo YS, Yeon JE and Byun KS: Comparison of lamivudine plus adefovir therapy versus entecavir with or without adefovir therapy for adefovir-resistant chronic hepatitis B. J Clin Gastroenterol. 48:889–895. 2014.PubMed/NCBI

40 

Marcellin P, Zoulim F, Hézode C, Causse X, Roche B, Truchi R, Pauwels A, Ouzan D, Dumortier J, Pageaux GP, et al: Effectiveness and safety of tenofovir disoproxil fumarate in chronic Hepatitis B: A 3-year, prospective, real-world study in france. Dig Dis Sci. 61:3072–3083. 2016. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Jia, J., Li, Y., Wei, C., Guo, R., Xu, H., Jia, Y. ... Gao, X. (2019). Factors associated with disease progression and viral replication in patients with chronic hepatitis B virus infection. Experimental and Therapeutic Medicine, 17, 4730-4740. https://doi.org/10.3892/etm.2019.7482
MLA
Jia, J., Li, Y., Wei, C., Guo, R., Xu, H., Jia, Y., Wu, Y., Li, Y., Wei, Z., Qi, X., Li, Z., Gao, X."Factors associated with disease progression and viral replication in patients with chronic hepatitis B virus infection". Experimental and Therapeutic Medicine 17.6 (2019): 4730-4740.
Chicago
Jia, J., Li, Y., Wei, C., Guo, R., Xu, H., Jia, Y., Wu, Y., Li, Y., Wei, Z., Qi, X., Li, Z., Gao, X."Factors associated with disease progression and viral replication in patients with chronic hepatitis B virus infection". Experimental and Therapeutic Medicine 17, no. 6 (2019): 4730-4740. https://doi.org/10.3892/etm.2019.7482